Guardant Health (GH) Tops Q4 EPS by 22c; Offers FY23 Revenue Guidance

Guardant Health (NASDAQ: GH) reported Q4 EPS of ($1.17), $0.22 better than the analyst estimate of ($1.39). Revenue for the quarter came in at $126.9 million versus the consensus estimate of $123.71 million.

GUIDANCE:

Guardant Health sees FY2023 revenue of $525-540 million, versus the consensus of $554 million.

For earnings history and earnings-related data on Guardant Health (GH) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
• Morgan Stanley upgrades CDW on stronger AI-driven server demand